Latest news and press releases about Editas Medicine, Inc. (EDIT): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia.
Price
| Price | $2.71 |
| Market Cap | $416M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 2.88 |
| EV / EBITDA | -4.25 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -196.63% |
| Return on Invested Capital | -46.81% |
| Return on Assets | -31.15% |
| Gross Margin | 56.90% |
| Operating Margin | -174.71% |
| Net Margin | -157.32% |
Related companies: ALLO · AVIR · CABA · CAPR · IMMP · KYTX · LYEL
Explore sector: Healthcare · Biotechnology
More sections of EDIT: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks